Novartis announces update to company's Board of Directors to take effect in February 2013
Basel, November 9, 2012 - Novartis announced today that Marjorie Yang has decided not to seek re-election to the Novartis Board of Directors at the Novartis Annual General Meeting in 2013. Ms. Yang joined the Novartis Board in 2007 and her current term is ending in 2013.
"We want to thank Ms. Yang for her important and valuable contributions as well as her dedication to Novartis," said Dr Daniel Vasella, Chairman of Novartis AG.
As customary, the company will provide shareholders with a list of proposals ahead of its Annual General Meeting scheduled for February 2013.
Novartis provides innovative healthcare solutions that address the evolving needs of patients and societies. Headquartered in Basel, Switzerland, Novartis offers a diversified portfolio to best meet these needs: innovative medicines, eye care, cost-saving generic pharmaceuticals, preventive vaccines and diagnostic tools, over-the-counter and animal health products. Novartis is the only global company with leading positions in these areas. In 2011, the Group's continuing operations achieved net sales of USD 58.6 billion, while approximately USD 9.6 billion (USD 9.2 billion excluding impairment and amortization charges) was invested in R&D throughout the Group. Novartis Group companies employ approximately 127,000 full-time-equivalent associates and operate in more than 140 countries around the world. For more information, please visit http://www.novartis.com.
Novartis is on Twitter. Sign up to follow @Novartis at http://twitter.com/novartis.
# # #
Novartis Media Relations
Central media line : +41 61 324 2200
Novartis Global Media Relations
+41 61 324 7999 (direct)
+41 79 593 4202 (mobile)
For Novartis multimedia content, please visit www.thenewsmarket.com/Novartis
For questions about the site or required registration, please contact: email@example.com.
Novartis Investor Relations
+41 61 324 7944
+41 61 324 7944
+41 61 324 1065
+1 212 830 2404
+41 61 324 8425
+1 212 830 2445
+41 61 324 7188
+1 212 830 2456